In this episode, we chatted with Molly Gibson, Co-Founder of Generate Biomedicines, a biotech that uses AI/ML to generate protein medicines and recently closed a $370M Series B financing. We discussed the key trends in computationally-powered drug discovery and bioplatforms, what it takes to commercialize early-stage biotechnology, and much more.

Founded in 2018 under the Flagship Pioneering ecosystem, Generate Biomedicines leverages machine intelligence to computationally generate de-novo (i.e., does-not-exist-in-nature) protein therapeutics.